After twenty-one years of breakthroughs that have largely solved the science behind cell and gene therapies (CGT), the mood at Advanced Therapies Week this year felt noticeably different – less about ‘what’s possible’ and more about ‘what’s practical.’
As global leaders gathered in San Diego for Phacilitate’s flagship event, one thing became clear: the future of cell and gene therapy won’t be defined by discovery alone, but by the systems, strategies and structures that bring those discoveries to patients at scale.
As life science PR experts, TALA worked with Phacilitate to spotlight the five major shifts emerging from this year’s conference. Informed by on-stage discussions, product launches, panel insights and conversations across the week, they point to the forces set to shape the next decade of advanced therapies.
In vivo takes the spotlight, making Point of Care manufacturing the next frontier
Advanced Therapies Week made one message impossible to miss: in vivo therapies are the next big thing in biotech. With growing big pharma investment signalling confidence in the science, the question is no longer about if we can do it but how we can scale it. Expanding access now hinges on addressing key barriers to point-of-care manufacturing, ensuring hospitals are ready to realistically deliver complex CGTs at scale.
New innovations debuting at Advanced Therapies Week aimed squarely at these bottlenecks. The launch of Nucleus Biologics’ Krakatoa® K500 system – the first bioreactor-scale, pod-based media and buffer manufacturing system delivers sterile solutions on demand and at point-of-use – tackles core challenges around cost and complexity of bedside delivery. CaseBioscience®’s two next-generation therapy-grade cryopreservation and hypothermic storage solutions support clinical cell therapy development.
Biotech funding is being rewritten
Insights from panel discussions highlighted that traditional funding models are no longer the only route to capital. One of the most talked-about moments at Advanced Therapies Week came from Siren Biotechnology’s success in Regulation Crowdfunding, which tested whether patient communities – particularly those affected by cancer – would invest directly in therapies under development.
The result was more than just early-stage biotech capital, it suggested a powerful new approach to patient engagement, where impacted communities can actively help to bring treatments to life.
Regulation is getting faster and more transparent
Experts shared how the regulatory landscape is evolving rapidly, with increased investment in biotech infrastructure worldwide and the need for companies to diversify across regions. With this comes a push for greater transparency and global alignment. Indeed, the U.S. FDA’s move toward real-time publication of Complete Response Letters (CRLs) promises greater clarity and industry learning – especially for complex cell, gene and RNA therapies.
For an industry dealing with highly complex therapies, this shift could be transformative. It enables faster learning, better preparation, and ultimately, more efficient paths to market. At the same time, companies are being urged to think globally from the outset, as multinational access is now a necessity rather than a luxury.
Breakthrough modalities reshape therapeutic possibilities
From LigronBio’s AI-driven gene therapies targeting neurodegenerative diseases like Alzheimer’s to D&P Bioinnovation’s regenerative bioimplants capable of rebuilding damaged oesophageal tissue, next‑generation CGT platforms presented at Advanced Therapies Week are expanding what advanced therapies can treat and how they can be delivered.
The field is moving beyond rare diseases with small patient populations toward broader, more mainstream indications. These innovations hint at a future where advanced therapies are not just lifesaving, but life-restoring and potentially even off-the-shelf.
Mentorship and visibility emerge as critical levers for closing CGT’s gender gap
Beyond the science and technology, Advanced Therapies Week highlighted a critical human factor: talent. Specifically, the need for greater female representation in senior scientific and leadership roles within the cell and gene therapy sector.
Survey data revealed persistent barriers, such as limited access to role models and uncertain career paths, while emphasising the importance of mentorship, sponsorship and non-linear transitions from academia to industry. Leadership diversity was shown to be critical for team building and policy design, with outreach programs vital to expanding the talent pool.
What defined Advanced Therapies Week 2026 wasn’t just innovation, it was alignment. Across manufacturing, funding, regulation and talent, the cell and gene therapies sector is coalescing around what it takes to deliver at scale. The science may have brought us here, but it’s execution that will carry these therapies the final mile to patients.